摘要
目的探讨顺铂分别联合吉西他滨及紫杉醇治疗复发性鼻咽癌对比研究。方法选取85例复发性鼻咽癌患者作为研究对象,根据随机数表法分为A组(42例)与B组(43例),A组接受顺铂+紫杉醇(TP)方案进行治疗,B组接受顺铂+吉西他滨(GP)方案治疗,观察两组近期疗效、肿瘤标志物[血小板源性生长因子(PDGF-BB)、血清上皮型钙黏蛋白(SE-CAD)]及毒副反应。结果两组近期疗效对比无统计学意义(P>0.05);治疗后,两组PDGF-BB、SE-CAD水平均下降,与本组治疗前对比有统计学意义(P<0.05);两组治疗后PDGF-BB、SE-CAD水平对比无统计学意义(P>0.05);B组胃肠道反应低于A组(P>0.05)。结论GP、TP方案用于复发性鼻咽癌均具有较好疗效,可抑制肿瘤生长,但与TP方案相比,GP方案胃肠道反应较小,安全性更高。
Objective To investigate the comparative study of cisplatin combined with gemcitabine and paclitaxel in the treatment of recurrent nasopharyngeal carcinoma.Methods 85 patients with recurrent nasopharyngeal carcinoma treated in our hospital from July 2018 to March 2020 were selected as the research objects.According to the random number table method,they were divided into group A(42 cases)and group B(43 cases).Group A received cisplatin+paclitaxel(TP)regimen,and group B received cisplatin+gemcitabine(GP)regimen.The short-term efficacy,tumor markers[platelet-derived growth factor(PDGF-BB),serum epithelial cadherin(SE-CAD)]and toxicity reactions were observed in the two groups.Results The short-term efficacy of the two groups was compared(P>0.05);after treatment,the levels of PDGF-BB and SE-CAD in the two groups were decreased,compared with those before treatment(P<0.05);the levels of PDGF-BB and SE-CAD in the two groups after treatment were compared(P>0.05);the gastrointestinal reaction in group B was lower than that in group A(P>0.05).Conclusion GP and TP regimens have good efficacy in recurrent nasopharyngeal carcinoma,which can inhibit tumor growth.However,compared with TP Regimen,GP regimen has less gastrointestinal reaction and higher safety.
作者
张战胜
曹静
Zhang Zhansheng;Cao Jing(Department of Oncology,Zhumadian Cancer Hospital,Zhumadian 463000,China;Department of Radiotherapy,Zhumadian First people's Hospital,Zhumadian 463000,China)
出处
《哈尔滨医药》
2021年第5期16-18,共3页
Harbin Medical Journal
关键词
鼻咽癌
吉西他滨
顺铂
紫杉醇
毒副反应
Nasopharyngeal carcinoma
Cisplatin
Gemcitabine
Paclitaxel
Toxicity reactions
